R&D Q3 Clinical trials round-up: July to September 2025 As the third quarter of 2025 draws to a close, the clinical research landscape has been marked by a surge of promising data and regulatory milestones.
News COVID-19 bites into Pfizer’s Q3, but biopharma revenues rise Pfizer is one of the front-runners in the race to approve a COVID-19 vaccine
News COVID-19 ventilator demand fuels Philips Q3 sales Huge demand for ventilators and patient monitors spurred third quarter sales for Royal Philips, the company announced.
News Kidney biotech R1's $78m debut, and other biofinancings Biofinancing values have tailed off a bit after a strong start to 2026, but March has seen $50m+ rounds for R1, Crossbow, Excalipoint, and Prolium.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.